Walker D K
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK.
Br J Clin Pharmacol. 2004 Dec;58(6):601-8. doi: 10.1111/j.1365-2125.2004.02194.x.
The pharmaceutical industry continues to look for ways to reduce drug candidate attrition throughout the drug discovery and development process. A significant cause of attrition is due to safety issues arising either as a result of animal toxicity testing or in the clinical programme itself. A factor in the assessment of safety during early drug development is the pharmacokinetic profile of the compound. This allows safety data to be considered in the light of systemic drug exposure and therefore permits a quantitative assessment. This is particularly applicable when assessing the risk of a new chemical entity (NCE) in relation to safety parameters such as QT interval prolongation, where free plasma concentrations have been shown to be predictive of this property in relation to potency in preclinical testing. Prior to actual human exposure it is therefore important to be able to predict reliably the pharmacokinetic behaviour of an NCE in order to place such safety findings into a quantitative risk context. The emerging science of pharmacogenetics is likely to further our ability to assess the risk of NCEs to populations and individuals due to genetic variance. The drug metabolizing enzyme CYP2D6 has been recognized as providing the potential to result in widely differing systemic drug exposure in the patient population due to polymorphic expression. Further knowledge is likely to add to our understanding of population differences in exposure and response and aid in the identification of risk factors. One potential strategy for improving the effectiveness of the drug discovery process is to obtain clinical pharmacokinetic data more rapidly in order to assess more accurately the potential for both efficacy and safety of an NCE. Whilst procedures and technologies are available that allow this on the microdose scale, it is important that we recognize potential limitations of these approaches in order that they can be applied beneficially.
制药行业一直在寻找方法,以减少整个药物研发过程中候选药物的淘汰率。淘汰的一个重要原因是动物毒性试验或临床项目本身出现的安全问题。早期药物研发过程中安全性评估的一个因素是化合物的药代动力学特征。这使得安全数据能够根据药物的全身暴露情况来考虑,从而进行定量评估。这在评估新化学实体(NCE)与QT间期延长等安全参数相关的风险时尤为适用,在临床前试验中,游离血浆浓度已被证明可预测该特性与效力的关系。因此,在实际人体暴露之前,能够可靠地预测NCE的药代动力学行为,以便将此类安全发现置于定量风险背景下非常重要。新兴的药物遗传学科学可能会进一步提高我们评估由于基因变异导致NCE对人群和个体风险的能力。药物代谢酶CYP2D6已被认为由于多态性表达,有可能导致患者群体中全身药物暴露差异很大。更多的知识可能会加深我们对暴露和反应人群差异的理解,并有助于识别风险因素。提高药物研发过程有效性的一个潜在策略是更快地获得临床药代动力学数据,以便更准确地评估NCE的疗效和安全性潜力。虽然有程序和技术可以在微剂量规模上做到这一点,但重要的是我们要认识到这些方法的潜在局限性,以便能够有益地应用它们。